Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study

Fu，Liang1; Zhang，Xilin2; Xiong，Juan3; Sun，Feng4; Weng，Taoping4; Li，Yang4; Zhang，Peize1; Li，Hui1; Yang，Qianting5; Cai，Yi6; Liang，Hancheng7; Chen，Qiuqi8; Wang，Zhaoqing1; Liu，Lei1; Chen，Xinchun6; Zhang，Wenhong4; Deng，Guofang1

2023-10-01

10.1016/j.ijid.2023.08.001

International Journal of Infectious Diseases   影响因子和分区

1201-9712

1878-3511

Objectives: Long, ineffective, and toxic regimens hinder the treatment of patients with multidrug-resistant tuberculosis (MDR-TB) and pre-extensive drug-resistant tuberculosis (pre-XDR-TB). Methods: We conducted a multicenter cohort study to prospectively evaluate the safety and efficacy of three 9-month, all-oral, 5-drug regimens. Regimen A (bedaquiline [Bdq]+linezolid [Lzd]+moxifloxacin [Mfx]+cycloserine [Cs]+pyrazinamide [Pza]) and Regimen B (Lzd+Mfx+Cs+clofazimine [Cfz]+Pza) were used to treat MDR-TB patients (Groups A and B, respectively, assigned according to the patient's treatment preference), while Regimen C (Bdq+Lzd+Cs+Cfz+Pza) was used to treat pre-XDR-TB patients (Group C). The primary endpoint was the occurrence of an unfavorable outcome within 12 months of treatment completion, regardless of regimen. Results: A total of 104 patients (34 in Group A, 46 in Group B, and 24 in Group C), with a median age of 35.5 (29.0-54.0) years, were included in the analysis population. At 12 months after treatment completion, five patients were deemed non-assessable. Of the remaining 99 participants, seven (7.1%) had an unfavorable outcome (including two deaths from any cause, four with treatment failure, and one loss to follow-up) and 92 (92.9%) had a favorable outcome. Culture conversion was achieved in 82.5% (80/97) of participants at month 2 and in 97.9% (94/97) of participants at month 6. Adverse events (AEs) resulting in drug adjustment occurred in 69.2% (72/104) of participants, mainly due to Lzd and Pza use. A QT interval prolongation of ≥ 500 ms occurred in 5.8% (6/104) of participants. Conclusion: The primary outcome of the three tailored, 9-month, all-oral, 5-drug regimens was satisfactory in the vast majority of MDR-TB and pre-XDR-TB patients, with manageable and reversible AEs.

Multidrug-resistant tuberculosis Pre-extensive drug-resistant tuberculosis Safety Short-course Treatment

SCI

英语

第一 ; 通讯

National Key Research and Development Program of China[2019YFC0840602];National Key Research and Development Program of China[2020YFA0907200];National Natural Science Foundation of China[82070016];Shenzhen Scientific and Technological Foundation[JCYJ20180228162112889];Shenzhen Scientific and Technological Foundation[KCXFZ202002011007083];

Infectious Diseases

Infectious Diseases

WOS:001077460500001

ELSEVIER SCI LTD

IMMUNOLOGY

2-s2.0-85170086609

Scopus

1.Division Two of Pulmonary Diseases Department,National Clinical Research Center for Infectious Disease (Shenzhen),Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis),Shenzhen Third People's Hospital,Southern University of Science and Technology,Shenzhen,China
2.Tuberculosis Prevention and Control Department,The Fourth People's Hospital of Foshan,Foshan,China
3.Health Science Center,Shenzhen University,Shenzhen,China
4.Department of Infectious Diseases,Huashan Hospital,Fudan University,Shanghai,China
5.Guangdong Key Lab for Diagnosis & Treatment of Emerging Infectious Disease,Shenzhen Third People's Hospital,National Clinical Research Center for Infectious Disease,Southern University of Science and Technology,Shenzhen,China
6.Department of Pathogen Biology,Guangdong Key Laboratory of Regional Immunity and Diseases,Shenzhen University School of Medicine,Shenzhen,China
7.Division Two of Tuberculosis Diseases Department,The Sixth People's Hospital of Dongguan,Dongguan,China
8.Graduate School of Guangdong Medical University,Zhanjiang,China

Fu，Liang,Zhang，Xilin,Xiong，Juan,et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study[J]. International Journal of Infectious Diseases,2023,135:101-108.

Fu，Liang.,Zhang，Xilin.,Xiong，Juan.,Sun，Feng.,Weng，Taoping.,...&Deng，Guofang.(2023).Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study.International Journal of Infectious Diseases,135,101-108.

Fu，Liang,et al."Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study".International Journal of Infectious Diseases 135(2023):101-108.